Latest / DDReg Knowledge Capsule
Malaysia NPRA 2026: Fast Route for Biosimilar Registration
Welcome to the DDREG Knowledge Capsule. In this episode, we unpack the National Pharmaceutical Regulatory Agency's (NPRA) landmark 2026 reliance pilot pathway in Malaysia. We explore how eligible biosimilars with prior US FDA or EMA approval can now access an accelerated 60-working-day registration timeline.However, this rapid timeline is far from automatic.
We break down the strict parameters sponsors must navigate to succeed, including the critical three-month post-approval submission window, rigorous dossier sameness requirements, and NPRA-specific local additions like ASEAN Zone IVb…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.